Compare HSIC & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HSIC | RGEN |
|---|---|---|
| Founded | 1932 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 8.1B |
| IPO Year | 1996 | 1995 |
| Metric | HSIC | RGEN |
|---|---|---|
| Price | $76.81 | $123.29 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 11 |
| Target Price | $84.50 | ★ $173.09 |
| AVG Volume (30 Days) | ★ 1.5M | 767.3K |
| Earning Date | 01-01-0001 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 7.21 | ★ 286.96 |
| EPS | ★ 3.27 | 0.86 |
| Revenue | ★ $13,201,995,000.00 | $141,236,000.00 |
| Revenue This Year | $6.15 | $14.11 |
| Revenue Next Year | $3.62 | $14.71 |
| P/E Ratio | ★ $23.81 | $139.37 |
| Revenue Growth | 5.94 | ★ 35.10 |
| 52 Week Low | $60.56 | $102.97 |
| 52 Week High | $89.29 | $175.77 |
| Indicator | HSIC | RGEN |
|---|---|---|
| Relative Strength Index (RSI) | 41.69 | 33.82 |
| Support Level | $74.66 | $121.25 |
| Resistance Level | $79.37 | $132.51 |
| Average True Range (ATR) | 2.58 | 6.58 |
| MACD | -0.55 | -0.05 |
| Stochastic Oscillator | 5.18 | 15.23 |
Henry Schein Inc is a solutions company for healthcare professionals. It offers healthcare equipment, products, and services to office-based dental and medical practitioners, as well as alternative sites of care. The company's reportable segments are: Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology. It generates maximum revenue from the Global Distribution and Value-Added Services segment, which includes distribution to the dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services. This segment also includes value-added services such as financial services, continuing education services, consulting, and other practice services.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.